Atomwise to collaborate with Hansoh Pharma for AI-based drug discovery
Date: 2019-09-14   Author: Pankaj Singh  Category: #news

Atomwise to collaborate with Hansoh Pharma for AI-based drug discovery

Atomwise Inc., a leading developer of healthcare software that uses AI to discover medicines and agricultural compounds, recently announced that it will be collaborating with Hansoh Pharmaceutical Group Company Limited, a leading Chinese biopharmaceutical company, to discover and design potential drugs for around eleven confidential target proteins in different therapeutic areas.

Dr. Abraham Heifets, CEO, Atomwise, stated that interesting scientific discoveries have been taking place in Asia and there is a tremendous potential for leadership in the field of innovative drug discovery.  Hansoh Pharma is the company’s first partner in Asia.

Dr. Heifets further commented that Hansoh Pharma has been committed towards innovation and shares the company’s goal to have a global impact on the health of the patients.

Apparently, scientific teams from Hansoh Pharma and Atomwise will be collaborating closely on the programs. The combination of Atomwise’s medicinal chemistry, protein structure expertise and AI technologies and Hansoh Pharma’s manufacturing, commercial capabilities and fully integrated research and development has the potential to compress timelines and dramatically increase success for clinical development and drug discovery.

As per the terms of the collaboration, Atomwise will be receiving option exercise fees, confidential technology access fees, royalties and asset sale under collaboration or income based on sublicensing. Considering the historical average revenues generated from small molecule drugs, it has been estimated that the potential value of the collaboration deal is projected to reach US$1.5 billion.

Atomwise Inc., had invented the first learning AI technology for the discovery of structure-based small molecule drug. Atomwise was created in 2012 and performs tons of projects every year partnering with the world’s largest agrochemical and pharmaceutical companies along with more than hundred hospitals and universities in about 19 countries.

The company has raised more than $50 million from some leading venture capital enterprises to encourage and support the application and development of its AI technology.

Source Credit- https://www.businesswire.com/news/home/20190911005824/en/Atomwise-Announces-Largest-China-US-Collaboration-AI-Drug



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Curcumin Market 2020 – 2026 | Latest Trends, Demand and Growth Analysis
Author: Rahul Varpe

Decresearch has recently published a study titled ‘Global CURCUMIN Market Research Report’. In this report, analysts have provided a detailed evaluation of the global CURCUMIN market. The report is inclusive of a completely comprehensi...


Vitamin Ingredients market Business Opportunity and Application Analysis
Author: Rahul Varpe

Market Overview: –

 

The global Vitamin Ingredients market was valued at USD 8 Billion in 2017 and is projected to touch USD 10 Billion by 2024, developing at a CAGR of 5.9 % from 2019 to 2024

Decresearch h...


Retail 3D Printing Market Detail Analysis focusing on Application, Types and Regional Outlook
Author: Ashwin Naphade

MarketStudyReport.com adds Global Retail 3D Printing Market research focusing on the major drivers and restraints for the key players. It also provides analysis of the market share, segmentation, revenue forecasts and geographic regions of the mar...